SkinBioTherapeutics (SBTX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

15.88p
   
  • Change Today:
    -0.38p
  • 52 Week High: 19.50
  • 52 Week Low: 7.25
  • Currency: UK Pounds
  • Shares Issued: 228.44m
  • Volume: 615,738
  • Market Cap: £36.26m
  • Beta: 1.22

SkinBioTherapeutics shares jump on acquisition of topical cream maker

By Benjamin Chiou

Date: Friday 11 Oct 2024

LONDON (ShareCast) - (Sharecast News) - AIM-listed life sciences company SkinBioTherapeutics has announced the acquisition of Yorkshire-based health, hygiene and personal care products group Bio-Tech Solutions for £1.25m.
SkinBioTherapeutics said the deal brings the capabilities of manufacturing and packaging of health, hygiene and personal care products, as well as a future development platform for advanced topical creams.

The deal is being funded by a loan of £950,000 from a long-term shareholder along with a subscription for 2.35m shares at 10.64p (raising £250,000), along with the group's cash reserves.

After a fundraising in August, SkinBioTherapeutics had a cash position of £1.9m by the end of September, so still has "sufficient cash runway to support its operations through to Summer 2026".

"This is the second acquisition we have made as part of our buy and build strategy to generate immediate and longer-term benefits to the SkinBioTherapeutics Group," said chief executive Stuart Ashman.

"This is another building block to the solid scientific and financial foundations of the group and, with the successful completion of the Croda clinical studies, we are moving rapidly towards group profitability."

The stock was up nearly 10% at 12.34p by 1037 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

SBTX Market Data

Currency UK Pounds
Share Price 15.88p
Change Today -0.38p
% Change -2.31 %
52 Week High 19.50
52 Week Low 7.25
Volume 615,738
Shares Issued 228.44m
Market Cap £36.26m
Beta 1.22

SBTX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
72.99% below the market average72.99% below the market average72.99% below the market average72.99% below the market average72.99% below the market average
96% below the sector average96% below the sector average96% below the sector average96% below the sector average96% below the sector average
Price Trend
1.45% above the market average1.45% above the market average1.45% above the market average1.45% above the market average1.45% above the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average
Income Not Available
Growth
21.88% above the market average21.88% above the market average21.88% above the market average21.88% above the market average21.88% above the market average
11.76% above the sector average11.76% above the sector average11.76% above the sector average11.76% above the sector average11.76% above the sector average

SBTX Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
15:51 7,500 @ 15.95p
14:41 100,000 @ 15.75p
14:39 100,000 @ 15.75p
15:10 6 @ 15.50p
15:10 187 @ 16.00p

SBTX Key Personnel

CEO Stuart Ashman
CFO Manprit Singh Randhawa

Top of Page